CD8 Antikörper
Kurzübersicht für CD8 Antikörper (ABIN2704337)
Target
Alle CD8 Antikörper anzeigenReaktivität
Wirt
Klonalität
Konjugat
Applikation
Güteklasse
Klon
- 
    - 
                                            Verwendungszweck
- CD8 Unconjugated Antibody
- 
                                            Produktmerkmale
- Clone OKT8, a mouse monoclonal antibody, binds with a 32-34 kDa type I transmembrane glycoprotein known as CD8 a member of the immunoglobulin superfamily. OKT8 binds to CD8α, which forms either a homodimer or a heterodimer with CD8β. It is expressed on the surface of cytotoxic T cells, NK cells, cortical thymocytes, and on some dendritic cells. CD8 functions as a co-receptor for T-cell receptors and specifically binds to class I MHC for antigen recognition and T-cell activation.
- 
                                            Aufreinigung
- Purified
- 
                                            Reinheit
- >95 %
- 
                                            Immunogen
- Human peripheral blood T lymphocytes
- 
                                            Isotyp
- IgG2a, kappa
 
- 
                                            
- 
    
- 
    - 
                                            Applikationshinweise
- Optimal working dilution should be determined by the investigator.
- 
                                            Beschränkungen
- Nur für Forschungszwecke einsetzbar
 
- 
                                            
- 
    - 
                                            Format
- Liquid
- 
                                            Konzentration
- 0.5 mg/mL
- 
                                            Buffer
- PBS pH 7.2, 0.1 % (w/v) BSA, 0.09 % (w/v) sodium azide
- 
                                            Konservierungsmittel
- Sodium azide
- 
                                            Vorsichtsmaßnahmen
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
- 
                                            Lagerung
- 4 °C
 
- 
                                            
- 
    
- 
                    
 
                                     
                                     
                                    